Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.

Otsuka Medical Devices and Otsuka Pharmaceutical have launched the Paradise Ultrasound Renal Denervation system in Japan, with National Health Insurance coverage effective 1 March. The device, developed by US subsidiary Recor Medical, treats resistant hypertension by reducing sympathetic nerve overactivity surrounding renal arteries. The system targets patients whose blood pressure remains above target despite using three different antihypertensive medications, including a diuretic. This marks Japan's first ultrasound renal denervation treatment. The Paradise system received FDA approval in the US in November 2023. Under a co-promotion agreement, both Otsuka companies will leverage their cardiovascular and renal expertise to deliver the treatment according to guidelines established by Japanese medical societies. The system offers a new option for resistant hypertension patients at high risk of serious cardiovascular complications.

Sky Labs has signed an exclusive distribution agreement with Otsuka Pharmaceutical to launch its ring-type blood pressure monitor, CART BP pro, in Japan's hospital and clinic market. The deal follows an MoU signed in December 2024. CART BP pro uses photoplethysmography technology to measure blood pressure without a cuff, allowing comfortable monitoring during daily activities and sleep. The device has already achieved success in South Korea, with over 150,000 prescriptions across 1,700 medical institutions since its 2023 approval and national health insurance coverage in 2024. Japan's hypertension market includes approximately 43 million patients, with 29% failing to achieve blood pressure control and 33% unaware of their condition. Sky Labs will leverage Otsuka's distribution network and cardiovascular expertise to expand across Japanese healthcare facilities.